51% Higher Major Heart Risk From Off Label Testosterone Therapy

Testosterone therapy can help men with confirmed testosterone deficiency, but it carries specific medical risks, especially when started without a confirmed diagnosis. The biggest concerns are cardiovascular events, elevated red blood cell counts, fertility suppression, prostate changes, and worsened sleep apnea. The TRAVERSE trial found no added heart attack or stroke risk in carefully screened hypogonadal men, while a separate large cohort tied off-label use to significantly higher long-term cardiovascular events. The gap between those two findings is the whole story: get the diagnosis right, monitor consistently, and most risks become manageable rather than dangerous.

TL;DR:

• Men prescribed testosterone therapy should have confirmed hypogonadism through repeat testing before starting treatment to reduce long-term cardiovascular risks.
• Regular monitoring of hematocrit levels is essential, especially if they approach or exceed 54%, to prevent blood thickening and clotting complications.
• Men who start TRT without confirmed deficiency face a 51% higher risk of major adverse cardiovascular events compared to those with verified low testosterone levels.
• The choice of delivery method influences risk patterns, with injections causing peaks and troughs, while gels and patches offer steadier hormone levels but have their own cautionary considerations.
• Proper clinical oversight involving baseline assessment, ongoing lab tests, and symptom tracking significantly lowers the chance of adverse effects and long-term health issues.

Table of Contents

• Testosterone Therapy Risks: A Quick Reference Checklist
• Cardiovascular Evidence: Trials Versus Real-World Cohorts
• Blood-Related Risks: Hematocrit, Erythrocytosis, and Clot Danger
• Fertility and Reproductive Effects: What TRT Does to Sperm Production
• Prostate Health and PSA: Separating Real Risk From Old Fears
• Sleep Apnea and Other Short-Term Side Effects
• Who Should Avoid or Delay Testosterone Therapy
• Monitoring Schedule: Tests, Timing, and Red Flags
• Why Clinician Oversight Changes the Risk Calculation
• Liver Toxicity and Metabolic Effects
• Impact on Lipid Profiles and Diabetes Risk
• Long-Term Cancer Risks Beyond the Prostate
• Risk Differences by Administration Route
• The Real Lesson Buried in the TRT Data
• A Clinician-Supervised Path to Hormone Support
• Sources
• FAQ

Testosterone Therapy Risks: A Quick Reference Checklist

Every man weighing TRT risks and benefits deserves a straight list of what can go wrong and what a clinician actually watches for. This isn’t a scare list. It’s the same checklist a competent prescriber runs through at every visit.

• Cardiovascular events (heart attack, stroke, atrial fibrillation). Why it matters: testosterone can thicken the blood and raise blood pressure, both of which strain the heart. Watch for: chest pain, irregular heartbeat, or new shortness of breath.
• Erythrocytosis and clotting risk. Why it matters: testosterone stimulates red blood cell production, and too much makes blood sludgy and clot-prone. Watch for: headaches, dizziness, or a hematocrit reading creeping upward on routine labs.
• Fertility suppression. Why it matters: exogenous testosterone shuts down the body’s own signal to produce sperm. Watch for: shrinking testicles or a semen analysis showing low counts.
• Prostate and PSA changes. Why it matters: testosterone can accelerate growth of existing prostate tissue, benign or otherwise. Watch for: a PSA level that rises quickly between tests.
• Sleep apnea worsening. Why it matters: testosterone can relax airway muscles further during sleep. Watch for: louder snoring, witnessed pauses in breathing, or new daytime fatigue.
• Edema, acne, and gynecomastia. Why it matters: fluid retention and hormone conversion to estrogen cause these cosmetic and comfort issues. Watch for: swollen ankles, oily skin breakouts, or tender breast tissue.
• Mood and behavioral changes. Why it matters: supraphysiologic or fluctuating testosterone levels can affect irritability and emotional regulation. Watch for: uncharacteristic anger, anxiety, or mood swings that a partner or friend notices before you do.

Statistic to know: A large cohort study following more than 350,000 men found that starting testosterone therapy without confirmed hypogonadism was linked to a 51% higher risk of major adverse cardiovascular events compared with men who had a confirmed deficiency before starting. That single number is the strongest argument for testing before treating, not after.

Cardiovascular Evidence: Trials Versus Real-World Cohorts

Two well-regarded sources reach seemingly different conclusions, and understanding why matters more than picking a side. The TRAVERSE trial, published in the New England Journal of Medicine, followed middle-aged and older men with confirmed hypogonadism and elevated baseline cardiovascular risk for roughly 22 to 33 months. Testosterone replacement turned out to be noninferior to placebo for the primary endpoint of major adverse cardiac events, with a hazard ratio of 0.96. That’s genuinely reassuring for men who fit the trial’s profile: diagnosed, symptomatic, and monitored under a research protocol.

But TRAVERSE also flagged something worth taking seriously. Men on testosterone had higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury than men on placebo. Noninferior on the main heart-attack-and-stroke metric doesn’t mean risk-free across the board.

Then there’s the large observational cohort published in eBioMedicine, which looked at real-world prescribing rather than a controlled trial. It found that men who started testosterone without documented evidence of deficiency carried a hazard ratio of 1.51 for MACE and higher all-cause mortality compared with men who had a confirmed diagnosis. The mechanism is plausible: erythrocytosis thickens the blood, testosterone can nudge blood pressure upward, and men who never had true deficiency get all of the physiological changes with none of the underlying benefit that might offset them.

The practical takeaway: the diagnosis you walk in with predicts your risk more than the medication itself. A man with confirmed low testosterone, a reasonable cardiovascular risk profile, and a clinician tracking his hematocrit is in a very different position than a man who started TRT based on symptoms alone and a single borderline lab.

Blood-Related Risks: Hematocrit, Erythrocytosis, and Clot Danger

Erythrocytosis, an abnormal rise in red blood cell mass, is one of the most common and most underappreciated testosterone side effects. Testosterone stimulates the bone marrow to produce more red blood cells, and in some men that response runs well past what’s healthy. Thicker blood doesn’t flow as efficiently, and it raises the odds of clot formation, which is one plausible driver behind the atrial fibrillation and pulmonary embolism signals seen in TRAVERSE.

Clinicians commonly use a hematocrit above 54% as an action point, though exact thresholds vary by practice. When a man crosses that line, the standard responses are:

• Dose reduction to lower the stimulus driving red cell production.
• Temporary hold on therapy until levels normalize.
• Therapeutic phlebotomy (essentially a blood donation) to bring hematocrit down quickly when levels are high enough to raise clotting concern.

The numbers that matter: a comprehensive review of TRT risks published through NIH’s PMC database lists erythrocytosis alongside peripheral edema and cardiac and hepatic dysfunction as core monitoring priorities for anyone on testosterone therapy.

The connection to cardiovascular risk isn’t theoretical. Elevated hematocrit is one of the few modifiable variables a clinician can catch on a routine blood draw, weeks before it becomes a hospital visit. That’s also why a single baseline test and a prescription handed out without a follow-up plan is one of the more common ways TRT goes wrong. If your hematocrit is trending upward and nobody has mentioned it, that’s a conversation worth forcing at your next visit.

Fertility and Reproductive Effects: What TRT Does to Sperm Production

Exogenous testosterone suppresses the pituitary signals (LH and FSH) that tell the testicles to make sperm and produce their own testosterone. The body reads the outside supply as “enough” and shuts down its internal production line. That’s not a side effect in the traditional sense. It’s how the therapy works, and it applies to essentially every man on TRT regardless of formulation.

The visible result is often testicular shrinkage, and the less visible result is a drop in sperm count that can reach clinically significant infertility in many men. Recovery is possible but far from guaranteed to be quick. Sperm counts and testicular volume can take months to years to return to baseline after stopping, and a subset of men experience prolonged or incomplete recovery.

For men who want children during or after treatment, there are real options worth discussing before starting:

• Sperm cryopreservation before beginning therapy, banking a fertility option regardless of what TRT does afterward.
• hCG or clomiphene as alternatives or adjuncts that stimulate the body’s own testosterone and sperm production rather than replacing it externally.
• Referral to reproductive endocrinology for men who’ve already started TRT and are struggling to conceive.

Pro Tip: If having children in the next few years is even a possibility, raise it before your first prescription, not after your semen analysis comes back low. Sperm banking is far simpler as a planned step than as damage control.

Prostate Health and PSA: Separating Real Risk From Old Fears

For decades, testosterone therapy carried a reputation for fueling prostate cancer. The current trial evidence doesn’t support that fear in the way older guidance assumed. In men who are properly screened before starting, testosterone has not been shown to increase new prostate cancer diagnoses. What it can do is raise PSA levels and accelerate growth in prostate tissue that already has disease, benign or malignant, sitting quietly.

That distinction is why baseline screening isn’t optional. Before starting therapy, a clinician should check:

• Baseline PSA, ideally with a second confirmatory reading if the first is borderline.
• Digital rectal exam, considered on a case-by-case basis depending on age and risk factors.
• Family history of prostate cancer, which shifts the risk conversation even when current labs look normal.

Follow-up matters just as much as the baseline. A PSA that rises sharply between two testing intervals, rather than drifting slowly, is the pattern that should trigger a pause in therapy and a urology referral. Men with an elevated baseline PSA or a strong family history need a frank conversation about whether TRT is worth starting at all, and that conversation belongs to shared decision-making between patient and clinician rather than a one-size-fits-all rule.

Sleep Apnea and Other Short-Term Side Effects

Obstructive sleep apnea can worsen on testosterone therapy, and it’s one of the more commonly overlooked risks of testosterone treatment. Testosterone appears to affect airway muscle tone and breathing regulation during sleep, and men with undiagnosed or borderline sleep apnea sometimes see it tip into a clinically significant problem after starting therapy. A sleep apnea screening before treatment, and a low threshold for a sleep study if symptoms appear afterward, catches this early.

Beyond that, several short-term effects show up often enough to expect them:

• Acne, more common with injections that create testosterone peaks than with steadier delivery methods.
• Gynecomastia, from testosterone converting to estrogen in some men.
• Peripheral edema, fluid retention that shows up as ankle or leg swelling.
• Mood changes, ranging from irritability to genuine anxiety or depressive symptoms in some men.

Most of these respond to a dose adjustment or a formulation change. Severe or persistent versions, particularly significant mood disturbance or breathing problems during sleep, are the signal to pause therapy and get a specialist involved rather than pushing through.

Who Should Avoid or Delay Testosterone Therapy

A pre-treatment checklist catches most of the harm before it starts. Here’s the sequence that reduces inappropriate prescribing:

1. Confirm the diagnosis with repeat testing. A single low testosterone reading isn’t enough. Repeat morning testosterone measurements on separate days, and consider free testosterone testing when total levels fall in a borderline range.
2. Review cardiovascular history. Prior heart disease, uncontrolled blood pressure, or a strong family history of early cardiac events changes the risk calculation significantly.
3. Check baseline hematocrit. Men who already run high normal are poor candidates for aggressive dosing and need closer monitoring from day one.
4. Assess prostate status. Baseline PSA and family history should be documented before the first prescription, not added later.
5. Screen for sleep apnea if there’s snoring, witnessed breathing pauses, or unexplained daytime fatigue.
6. Ask directly about fertility plans. If children are a possibility, discuss cryopreservation or alternatives like clomiphene before starting.

Skipping any of these steps is how a man ends up on therapy he didn’t need, chasing symptoms that had another cause entirely. For a fuller look at what those alternatives look like, reviewing TRT alternatives before committing to injections is worth the extra hour.

Monitoring Schedule: Tests, Timing, and Red Flags

A workable monitoring plan looks like this: baseline labs before the first dose, a check-in at 3 to 6 weeks after starting or adjusting dose, another at 3 months, then every 6 to 12 months once levels stabilize. Each visit should include AM total testosterone, hematocrit or hemoglobin, PSA, a lipid panel, and liver function tests, alongside a quick symptom check for mood, energy, and sexual function.

Three red flags deserve immediate action rather than waiting for the next scheduled visit:

• Hematocrit above 54% calls for a dose hold, reduction, or therapeutic phlebotomy.
• A rapid PSA rise between tests calls for a urology referral, not a wait-and-see approach.
• New chest pain, one-sided weakness, or slurred speech is an emergency room visit, full stop.

Pro Tip: Write your baseline symptom scores down before you start, and treat the follow-up labs as part of the deal you made when you agreed to treatment. Indefinite, unsupervised TRT with no lab checks is how avoidable complications turn into hospital visits. Reading your own testosterone blood work correctly is part of holding up your end of that deal.

Why Clinician Oversight Changes the Risk Calculation

A reputable telehealth platform runs every intake through licensed clinician review before anything gets prescribed, because so much of TRT’s risk comes down to two failure points: starting without a confirmed diagnosis, and stopping monitoring after the first prescription. Medications are US-compounded at FDA-registered pharmacies with purity testing, and unlimited provider messaging means a hematocrit question doesn’t wait for a scheduled appointment. Lab-driven protocols close the gap that single-test starts and skipped follow-up labs leave open.

Liver Toxicity and Metabolic Effects

Liver strain from injectable or transdermal testosterone is far less common than it was with older oral anabolic steroids, which carried a well-documented risk of liver damage due to how they were chemically altered to survive digestion. Modern testosterone formulations, gels, injections, and patches, bypass that first-pass liver metabolism issue, which is a large part of why liver toxicity ranks lower on the TRT risk list than it does for illicit steroid use.

That doesn’t mean the liver is irrelevant. The NIH review of TRT risks lists hepatic dysfunction among the effects worth monitoring, which is why liver function tests belong in a standard lab panel alongside hematocrit and PSA. Elevated liver enzymes on routine testing are uncommon but not unheard of, particularly in men using higher doses or combining testosterone with other substances that also tax the liver.

Metabolically, testosterone’s relationship with the liver connects to broader hormone regulation. Testosterone deficiency itself is associated with insulin resistance and fatty liver changes in some men, which complicates the picture. In men with confirmed deficiency, restoring testosterone to a normal range sometimes improves metabolic markers rather than worsening them. In men without a real deficiency, that potential benefit doesn’t exist, and the medication becomes pure exposure with no offsetting upside.

Impact on Lipid Profiles and Diabetes Risk

Testosterone therapy’s effect on cholesterol tends to be modest and formulation-dependent. Some studies show a slight decrease in HDL, the “good” cholesterol, particularly with certain injectable regimens, while LDL and total cholesterol changes are usually smaller and less consistent. This is why a lipid panel belongs in the standard monitoring rotation rather than being treated as optional.

The diabetes and insulin-sensitivity picture is more nuanced. Men with confirmed low testosterone often have higher rates of insulin resistance and type 2 diabetes to begin with, and some evidence suggests treating a genuine deficiency can modestly improve insulin sensitivity and body composition. That’s a very different scenario from prescribing testosterone to a man with normal levels and hoping for a metabolic boost. There’s no solid evidence that testosterone therapy meaningfully lowers diabetes risk in men who didn’t have a deficiency to begin with, and starting therapy on that premise alone isn’t supported by the current trial evidence.

Practically, this means your metabolic panel and lipid results aren’t just background paperwork. A modest drop in HDL that shows up alongside other changes, weight gain, blood pressure creep, poor sleep, might be worth flagging to your prescriber rather than dismissing as unrelated noise.

Long-Term Cancer Risks Beyond the Prostate

Prostate cancer gets most of the attention in cancer-risk conversations about TRT, but it isn’t the only tissue that responds to hormone signals. Breast tissue in men is hormonally sensitive too, and while male breast cancer is rare in absolute terms, testosterone’s conversion to estrogen in the body means gynecomastia, benign breast tissue growth, is a far more common finding than actual malignancy. The two are worth distinguishing: tender or swollen breast tissue is usually benign and dose-related, but any hard, fixed, or asymmetric lump deserves a direct exam rather than an assumption.

Beyond the prostate and breast tissue, the long-term cancer data on testosterone therapy is genuinely limited. TRAVERSE and most major trials weren’t designed or powered specifically to detect rare cancer signals over decades, which means the honest answer for a man asking about 20-year cancer risk is that the evidence base doesn’t extend that far with confidence. This is a case where “no signal found” is different from “proven safe,” and it’s worth saying plainly rather than papering over with false reassurance.

Risk Differences by Administration Route

Injections, gels, and patches don’t carry identical risk profiles, even though the hormone itself is the same. Injectable testosterone, typically given every one to two weeks, creates peaks and troughs in blood levels. Those peaks are linked to a higher rate of acne, mood swings, and more pronounced erythrocytosis, since the bone marrow gets hit with a stronger stimulus right after each dose.

Topical gels and creams deliver a steadier level with fewer sharp peaks, which tends to mean less dramatic hematocrit swings, but they carry their own quirk: transfer risk to a partner or child through skin contact if applied without care. Patches deliver similarly steady levels but are more prone to skin irritation at the application site, and adherence tends to run lower simply because daily patch changes are more disruptive than a weekly injection or a shorter-acting gel routine.

None of these routes eliminates the core risks discussed throughout this article, cardiovascular strain, erythrocytosis, fertility suppression, prostate stimulation. What changes is the pattern of how those risks show up and how easy they are to catch on routine monitoring. A breakdown of specific formulations is worth reading if you’re deciding between routes rather than just accepting whatever your prescriber defaults to.

The Real Lesson Buried in the TRT Data

The conventional wisdom on testosterone therapy risk splits into two unhelpful camps: one insists TRT is dangerous and best avoided, the other treats it as a low-risk fix for feeling tired at 45. Neither holds up against the actual evidence. TRAVERSE shows that properly diagnosed men, screened and monitored, don’t carry meaningfully elevated cardiac risk. The cohort data shows that men who never had a real deficiency, treated anyway, carry substantially higher long-term risk. Those aren’t contradictory findings. They’re the same finding stated from two different starting points.

What gets underestimated is how much the diagnostic step matters compared to the drug itself. Men fixate on injection versus gel, or brand versus compounded, when the bigger variable is whether they ever had confirmed hypogonadism in the first place. If there’s one place to spend your skepticism, it’s there, not on the delivery method.

My honest read: the men who do well long-term on testosterone therapy are the ones treating it like a managed medical condition rather than a supplement. Labs get drawn. PSA gets tracked. Hematocrit gets watched. That’s not excessive caution. It’s the difference between a therapy that helps and one that quietly accumulates risk nobody’s tracking.

— Amy

A Clinician-Supervised Path to Hormone Support

If the checklist above left you thinking you’d rather not manage this alone, that’s the point of clinician oversight. Revive Meds reviews every intake through a licensed clinician before anything gets prescribed, builds protocols around actual lab values rather than a single symptom checklist, and compounds medications at FDA-registered US pharmacies with purity testing on every batch. Unlimited provider messaging means a hematocrit question or a mood change gets addressed between visits, not at the next scheduled appointment months later.

To be direct: testosterone therapy isn’t right for every man, and no responsible clinician will prescribe it without confirming a real deficiency first through proper lab work. If you’ve had symptoms, want your levels checked correctly, and want a provider who treats monitoring as part of the plan rather than an afterthought, start a clinical intake for hormone support and see whether TRT is actually the right fit for your labs and history.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

• Cardiovascular Safety of Testosterone-Replacement Therapy | NEJM
• Testosterone therapy without evidence of deficiency may boost heart risk — Harvard Health

FAQ

Why Are Some Doctors Cautious About Testosterone Therapy?

Many clinicians worry about overprescribing to men without a confirmed deficiency, since the large cohort data shows notably higher cardiovascular risk in that group. The caution is about diagnostic rigor and follow-up, not a blanket rejection of the therapy itself.

Does TRT Shorten Your Lifespan?

There’s no solid evidence that testosterone therapy shortens life expectancy in men with confirmed hypogonadism who are properly monitored, based on the noninferior mortality-related outcomes in the TRAVERSE trial. The risk of higher mortality appears concentrated in men started on therapy without a confirmed deficiency, not in appropriately diagnosed patients.

Is Testosterone Therapy Safe for Men Over 50?

TRT can be safe when a real deficiency is confirmed through repeat lab testing and cardiovascular, prostate, and sleep apnea risks are screened beforehand. Age alone isn’t disqualifying, but older men often carry more of the baseline risk factors that make careful monitoring, not skipping it, essential.

What’s the Safest Form of Testosterone Therapy?

No single delivery method is universally “safest,” since injections, gels, and patches each carry a different risk pattern rather than a different overall risk level. Steadier delivery methods tend to produce smoother hormone levels with fewer peaks, which can mean less dramatic swings in red blood cell counts, but the right choice depends on your labs, lifestyle, and how closely your prescriber tracks your monitoring, something Revive Meds structures around lab-driven protocols rather than a one-size-fits-all default.

How Often Should Labs Be Checked During TRT?

A common schedule includes baseline labs before starting, a recheck at 3 to 6 weeks after starting or adjusting dose, another at 3 months, then every 6 to 12 months once levels stabilize. Each check should include testosterone, hematocrit, PSA, lipids, and liver function tests.

Recommended

• Testosterone Therapy: A Clinician-Supervised TRT Guide
• What Your Testosterone Blood Work Actually Means
• TRT Alternatives: Real Benefits, Real Trade-Offs
• Boost Testosterone: Low T Symptoms, Causes, and What Works